These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16910584)

  • 1. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
    Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
    Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
    Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
    Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy.
    Noguchi K; Harada M; Masuda M; Takeda M; Kinoshita Y; Fukushima S; Miyai K; Fukuoka H; Hosaka M
    Int J Urol; 1998 Sep; 5(5):466-70. PubMed ID: 9781436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH].
    Noguchi K; Takeda M; Hosaka M; Kubota Y
    Hinyokika Kiyo; 2002 May; 48(5):269-73. PubMed ID: 12094708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia.
    Stone NN; Clejan SJ
    J Androl; 1991; 12(6):376-80. PubMed ID: 1722793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
    Kanimoto Y; Okada K
    Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
    Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
    Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
    Iguchi H; Ikeuchi T; Kai Y; Yoshida H
    Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
    Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
    Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fundamental and clinical study of the anti-prostatic effect of allylestrenol].
    Yamanaka H; Kosaku N; Makino T; Shida K
    Hinyokika Kiyo; 1983 Sep; 29(9):1133-45. PubMed ID: 6203385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.